Gsk (GLAXF) Gains from Investment Securities (2009 - 2026)

Gsk's Gains from Investment Securities history runs 18 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 70.81% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$149.3 million (up 18.88% YoY), while the FY2025 annual figure was -$121.3 million, up 7.87% from the prior year.
• Gains from Investment Securities was -$8.1 million for Q1 2026 at Gsk, up from -$53.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of -$8.1 million in Q1 2026 to a low of -$73.2 million in Q4 2023.
• Historically, Gains from Investment Securities has averaged -$49.2 million across 5 years, with a median of -$60.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities declined 21.35% in 2025, then surged 70.81% in 2026.
• A 5-year view of Gains from Investment Securities shows it stood at -$69.2 million in 2022, then dropped by 5.82% to -$73.2 million in 2023, then advanced by 17.62% to -$60.3 million in 2024, then increased by 11.8% to -$53.2 million in 2025, then jumped by 84.8% to -$8.1 million in 2026.
• The last three Gains from Investment Securities figures came in at -$8.1 million (Q1 2026), -$53.2 million (Q4 2025), and -$27.7 million (Q1 2025), per Business Quant data.